IKT Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical stage pharmaceutical company that is engaged in developing therapeutics for neurodegenerative disease inside and outside of the brain. The company develops IkT-148009, a brain penetrant c-Abl protein kinase inhibitor which is under phase I trial for Parkinson's disease (PD) and to treat early-stage PD patients with GI complications, as well as for the treatment of dysphagia and neurogenic constipation. Its clinical development product includes IkT-001Pro, an Abl kinase inhibitor prodrug of the anticancer agent for chronic myelogenous leukemia; and research phase products include IkT-01427 for progressive multifocal leukoencephalopathy, as well as IKT-148X to treat dementia with lewy body and multiple system atrophy. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; the M. D. Anderson Cancer Center; and Memorial Sloan-Kettering Cancer Center. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

$0.74
As of 06/30/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/23/2020
Outstanding shares:  25,227,051
Average volume:  143,781
Market cap:   $20,181,641
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -1.15
PB ratio:   0.57
PS ratio:   11.60
Return on equity:   -49.37%
Net income %:   -965.21%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy